BioSpace News Archive

The study was published in the American Journal of Obstetrics & Gynecology and is the first to validate biomarkers that reliably differentiate between endometriosis and other gynecologic pathologies with high accuracy

Xeris Pharmaceuticals, Inc. announced a limited-time $0 copay offering for commercially eligible patients effective now through April 30, 2020 as a response to the COVID-19 pandemic.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund.

Translate Bio announced two updates related to its MRT5005 clinical development program in cystic fibrosis.

Disclaimer: This press release and our findings are solely intended as information for the scientific community.

Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis.

C2 PHARMA s.a.r.l., a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient, Digoxin.

Today Harvest Health & Recreation Inc. (CSE: HARV, OTCQX:HRVSF) (“Harvest”) and Verano Holdings, LLC (“Verano”) announced the mutual termination of the Business Combination Agreement dated April 22, 2019 (the “BCA”).

Endocanna Health, Inc. (“Endocanna” or “the Company”), a research and development biotechnology company specializing in endocannabinoid DNA testing and precision cannabinoid formulations, announced the formalization of a Scientific Board (“Science Board” or the “Board”) to drive investment in more clinical trials and research.

SWK Holdings Expects to Report Adjusted Earnings for Fourth Quarter and Year End 2019 of $4.3 to $4.7 million and $21.0 to $21.4 million, respectively